Literature DB >> 7523800

Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia.

C Dubois1, M H Schlageter, A de Gentile, N Balitrand, M E Toubert, I Krawice, P Fenaux, S Castaigne, Y Najean, L Degos.   

Abstract

Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias (AML) characterized by the presence of the t(15;17) translocation and the resulting PML/RAR alpha fusion proteins. To date APL is the only AML which is sufficiently sensitive to all-trans retinoic acid (ATRA) differentiating effect. We have recently reported that APL express and secrete hematopoietic growth factors (HGF) such as IL-1 beta, TNF alpha, and IL-6. In vivo ATRA alone allows achievement of complete remission in APL patients. One of ATRA therapy's drawbacks is the increase of peripheral blast cells often associated with the ATRA leukocyte activation syndrome. To determine if this specific side-effect was linked to an increase of HGF release by APL cells, we studied the modulation of cytokine production by APL cells, we studied the modulation of cytokine production by APL samples (n = 12) before and after incubation with ATRA. ATRA failed to modulate TNF alpha, IL-6 or GM-CSF secretion levels; however, IL-8 levels decreased in 11 cases, and in four cases up-regulation of IL-1 beta and G-CSF protein expression was observed. These modulations were found to be linked to ATRA sensitivity as ATRA failed to modulate cytokine production in non-APL cells (n = 8). Interestingly, the increase of IL-1 beta and G-CSF production in the presence of ATRA was highly correlated to an increase in APL cell count in vitro and in vivo hyperleukocytosis, resulting in fatal outcome. IL-1 beta, TNF alpha, IL-6, and IL-8 are known to be implicated in leukocyte activation. The results of this study suggest that ATRA-induced hyperleukocytosis and ATRA leukocyte activation syndrome in APL may be inherent to the secretion of specific hematopoietic growth factors by the APL cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523800

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Late-onset differentiation syndrome in a child with acute promyelocytic leukemia.

Authors:  Hisao Yoshida; Risa Matsumura; Emiko Sato; Yoshiko Hashii; Hideaki Ohta; Keiichi Ozono
Journal:  Int J Hematol       Date:  2010-08-04       Impact factor: 2.490

Review 2.  Retinoic acid syndrome. Recognition, prevention and management.

Authors:  P Fenaux; S De Botton
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

3.  The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts.

Authors:  U Testa; F Grignani; P Samoggia; C Zanetti; R Riccioni; F Lo Coco; D Diverio; N Felli; C G Passerini; M Grell; P G Pelicci; C Peschle
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

Review 4.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

Review 5.  Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia.

Authors:  J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

6.  GATA Factor-Dependent Positive-Feedback Circuit in Acute Myeloid Leukemia Cells.

Authors:  Koichi R Katsumura; Irene M Ong; Andrew W DeVilbiss; Rajendran Sanalkumar; Emery H Bresnick
Journal:  Cell Rep       Date:  2016-08-18       Impact factor: 9.423

7.  ATRA Induced Reactive Hemophagocytosis: a Case Report.

Authors:  Monica Sharma; Jasmita Dass; Seema Tyagi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-09-08       Impact factor: 2.576

8.  Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Authors:  Anna Falanga; Laura Russo; Carmen J Tartari
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-21       Impact factor: 2.576

9.  Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid.

Authors:  C J Park; Y D Bae; J Y Choi; P S Heo; K S Lee; Y S Park; J A Lee
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

10.  HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.

Authors:  Lanlan Tang; Wenwen Chai; Fanghua Ye; Yan Yu; Lizhi Cao; Minghua Yang; Min Xie; Liangchun Yang
Journal:  Oncotarget       Date:  2017-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.